Breast Cancer Prognosis Using PrognostiCheck®
www.ipgdx.com
PrognostiCheck® uses phase angle from impedance analysis to detect the presence and severity of breast cancer, the effectiveness of treatment and survival of breast cancer patients who have the disease.
www.ipgdx.com
In a recent study of 259 breast cancer patients, 81 that were newly diagnosed, 178 that had received prior treatment 56 with stage - I disease at diagnosis, 110 with stage - II, 46 with stage - III and 34 with stage - IV. http://www.virtualcancercentre.com/uploads/VMC/TreatmentImages/1247_Breast_Mid.jpg
www.ipgdx.com
Their ages ranged from 25 to 74 years old. The median phase angle was 5.6 degrees.
www.ipgdx.com
Patients with phase angle less than or equal to 5.6° had a median survival of only 23.1 months, while those greater than 5.6° had 49.9 months. http://www.virtualmedicalcentre.com/uploads/VMC/DiseaseImages/1250_Breast_LCIS_Med.jpg
www.ipgdx.com
PrognostiCheck® is a scoring system that interprets a measured electrical value that illustrates the health of the cell membrane. It can be used to provide critically important information to patients, their families and physicians on survival in breast cancer and all other diseases.
www.ipgdx.com
The measurement of phase angle includes the combined effects of the body’s fluids and cells specifically the cellular membranes of the human body. By measuring these values PrognostiCheck® reports information heretofore not available to patients, families and their physicians.
www.ipgdx.com
Lower phase angle values indicate illnesses by seeing cell death or decreased cell integrity, while higher phase angle values indicate more intact cell membranes and a healthier person. http://graphics8.nytimes.com/images/2007/08/01/health/adam/9294.jpg
www.ipgdx.com
http://www.medindia.net/patients/patientInfo/images/Breast_cancer.gif
In breast cancer the severity of the disease can be seen and reported by PrognostiCheck® and guide the patient to the level of care they need sooner and easier. www.ipgdx.com
The PrognostiCheck® results come from a simple noninvasive test that is quickly done has no side effects and is easily repeated to show change over time.
www.ipgdx.com
It is especially sensitive to changes and precise with nearly perfect test re-test reliability (0.98 out of 1). The device used for the test is an FDA 510(k) approved Class II medical instrument.
www.ipgdx.com
Breast Cancer Prognosis Using PrognostiCheck® By IPGDx, LLC www.ipgdx.com
[email protected] [email protected] www.ipgdx.com